TKI Dose Reduction and Remission in Patients With CML
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
British Journal of Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
TKI Dose Reduction Can Effectively Maintain Major Molecular Remission in Patients With Chronic Myeloid Leukaemia
Br. J. Haematol 2020 Dec 24;[EPub Ahead of Print], S Claudiani, JF Apperley, R Szydlo, A Khan, G Nesr, C Hayden, A J Innes, K Dominy, P Foskett, L Foroni, J Khorashad, D MilojkovicFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.